HD2026 Milton Wexler Biennial Symposium Day 3
Day 3 of #HD2026 put HTT under the microscope. Researchers shared new insights into HTT1a, next-generation HTT-lowering approaches, somatic expansion, brain circuitry, and why boosting healthy HTT might help. Read our roundup here. Read more
HD2026 Milton Wexler Biennial Symposium Day 2
⏱️ 23 min read | Day 2 of #HD2026 brought us updates on the mechanics of somatic instability, new ways to track HD in people, AI tools to help drive research forward, and developments in our understanding of the HTT protein. Catch up right here. Read more
HD2026 Milton Wexler Biennial Symposium Day 1
⏱️ 28 min read | Day1 of HD2026 is a wrap! From what human brains can teach us about HD, to HTT1a, somatic CAG expansion and the normal biology of HTT, today’s talks spanned the spectrum from fundamental biology to potential treatments. Read more
Prilenia shares HD trial data with CHDI to help future research
Clinical trial data can drive discovery long after a study ends. Prilenia donated placebo-arm data from 2 HD clinical trials to CHDI, a valuable resource for researchers to better understand placebo effects, HD progression and future trial design. Read more
Looking back and moving forward: Questions and lessons 4 weeks out from Roche’s disappointing news
⏱️10min read | Roche’s decision to stop development of 2 HTT-lowering programmes is disappointing, but the story doesn’t end there. Years of research answered some key questions, raised many new ones, and will inform the next generation of HD trials. Read more
July 2026: This Month in Huntington’s Disease Research
⏱️ 8 min read | July was a hard month for Huntington’s disease research, with Roche ending two HD programs. But the month also brought promising new tools, a new player in somatic expansion, and important work on eating and self-awareness in HD. Read more
EN 
ES 
IT 
DE 
FR 